Lege Artis Medicinae

[ELEVATED RESTING HEART RATE AND THE RISK OF CARDIOVASCULAR MORTALITY]

BORBOLA József

NOVEMBER 30, 2006

Lege Artis Medicinae - 2007;17(01 klsz)

[In ancient times medical practitioners already knew that heart rate is a measure of the general condition of the soul and body. Worldwide epidemiologic studies in the past decades indicated that decreased resting heart rate, a parameter that can be simply measured, has a favourable direct effect on cardiovascular risk. This consistent beneficial risk-reducing effect can be clearly shown in the asymptomatic general population as well as in patients with hypertension, stable coronary artery disease, acute myocardial infarction and congestive heart failure irrespective of gender, age or ethnic origin. In the asymptomatic general population this beneficial effect is mainly due to reduced early coronary artery disease events and diminished risk of sudden cardiac death. Population studies have clearly shown that decreasing resting heart rate - either by physical exercise or medical treatment - improves cardiovascular survival, and decreases the overall and cardiovascular mortality. It seems reasonable to conclude that in modern pharmacotherapy of cardiovascular disease the use of selective heart rate lowering drugs that directly act on the pacemaker activity of the sinus node (If-channel blockers) are warranted.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[THE ROLE OF METABOLIC THERAPY IN THE TREATMENT OF STABLE RECURRENT ANGINA AFTER CORONARY REVASCULARIZATION]

TÓTH Csaba

[Current guidelines recommend drug treatment as firstline therapy for stable angina. If adequate symptom relief cannot be achieved with pharmacological management, or if myocardial ischaemia progresses, interventional revascularization procedures should be considered. Based on current guidelines, this should be either coronary artery bypass grafting or percutaneous coronary intervention. Recurrent angina refers to the persistence or reemergence of angina symptoms after a coronary revascularization procedure. This clinical situation indicates the repeat of coronarography as soon as possible. The repeated coronarography, however, often will not confirm progression or restenosis. The pathology of this clinical form of recurrent angina is not exactly known. As symptoms are frequently seen in the absence of abnormal coronary blood flow, vasodilator drugs are of limited effectiveness in recurrent angina. For this reason new, non-haemodynamic treatment approaches have been suggested. Among these, agents that help optimise cardiac metabolism are of particular interest. Trimetazidine acts on the energy metabolism of myocardial cells by reducing the reliance of myocardial metabolism on fatty acid oxidation and lifting the feedback inhibition of the glucose oxidation pathway. Moreover, trimetazidine reduces intracellular acidosis. These beneficial effects on cellular processes make trimetazidine the first representative of cardioprotective drugs. In randomized, placebo-controlled clinical trials on patients after revascularization, trimetazidine significantly reduced the number of angina episodes, decreased the ECG signs and the levels of biochemical markers of myocardial ischaemia, and improved exercise test parameters compared to placebo. The spectrum of benefits of this drug in stable angina ranges from decreasing the need for surgical intervention to improving the outcome and diminishing the symptoms of angina pectoris following revascularization.]

Lege Artis Medicinae

[Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/ adenosine triphosphate ratio in patients with heart failure]

HERCZEG Béla

Lege Artis Medicinae

[If-CHANNEL INHIBITION - A NEW APPROACH IN THE TREATMENT OF ISCHAEMIC HEART DISEASE]

TÓTH Kálmán

[Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If- channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.]

All articles in the issue

Related contents

Hypertension and nephrology

[Association between cyclothymic affective temperament and hypertension]

NEMCSIK János, BATTA Dóra, KŐRÖSI Beáta, RIHMER Zoltán

[Affective temperaments (cyclothymic, hypertymic, depressive, anxious, irritable) are stable parts of personality and after adolescent only their minor changes are detectable. Their connections with psychopathology is well-described; depressive temperament plays role in major depression, cyclothymic temperament in bipolar II disorder, while hyperthymic temperament in bipolar I disorder. Moreover, scientific data of the last decade suggest, that affective temperaments are also associated with somatic diseases. Cyclothymic temperament is supposed to have the closest connection with hypertension. The prevalence of hypertension is higher parallel with the presence of dominant cyclothymic affective temperament and in this condition the frequency of cardiovascular complications in hypertensive patients was also described to be higher. In chronic hypertensive patients cyclothymic temperament score is positively associated with systolic blood pressure and in women with the earlier development of hypertension. The background of these associations is probably based on the more prevalent presence of common risk factors (smoking, obesity, alcoholism) with more pronounced cyclothymic temperament. The scientific importance of the research of the associations of personality traits including affective temperaments with somatic disorders can help in the identification of higher risk patient subgroups.]

Hypertension and nephrology

[Focus on central arterial pressure. Beta blockers - one group of agents with different efficacy]

BARNA István

[Not only have beta blockers excellent antihypertensive effect but both in monotherapy and in combination they exert antiarrhythmic and antiischemic efficacy, as well. They are recommended on A level of evidence in the treatment of patients with primary hypertension. Certain beta blockers differ from each other considering their lipid solubility, membrane stabilizing effect and in many other characteristics which difference can be exploited in the treatment. Nebivolol increases the release of nitrogen oxide, it is metabolically neutral and has vasodilating and antioxidant effect. The consequence of the stiffness of the arterial wall is the rise of systolic blood pressure, the diminshed diastolic circulation in the coronary vessels, the increase of the central pulse pressure and the frequent occurrence of cardiovascular diseases. Various antihypertensive agents have different mode of action on central blood pressure and arterial stiffness. Comparing nebivolol/atenolol and nebivolol/bisoprolol, respectively, nebivolol decreased aortic pulse pressure with greater efficacy than other beta blockers. The extent of the reduction of blood pressure was the same in the nebivolol and atenolol group while the augmentation index decreased significantly among the patients receiving nebivolol. In addition to the well known beneficial effects of nebivolol recent studies proved another, yet still unknown and unique characteristic of this agent, i.e. favourable influence on arterial stiffness. It not only improves endothelial dysfunction which has emphasized role on development of atherosclerosis but - independently of its antihypertensive effect - it has favourable action on arterial stiffness, too. These features guarantee a decisive position in the treatment of arterial hypertension.]

Hypertension and nephrology

[The selective imidazoline I agonist rilmenidine in the combined antihypertensive therapy]

KÉKES Ede

[The rilmenidin as a imidazoline agonist drug strongly decreases the central simpathetic activity, renine release and the RAS activity. Because of these advantageous properties the peripheral vascular resistance falls and the blood pressure decreases. It is very useful especially in stress induced hypertension. The antihypertensive effects of ACE inhibitors and calciumantagonists are increased by rilmenidine. This drug decreases the inzuline resistance, it has a positive effect on the carbohydrate and fat metabolism, because it is useful as a complementary therapy in metabolic syndrome and of type II diabetes mellitus.]

Hypertension and nephrology

[Prevalence of overweight and obesity in hypertensive patients]

KISS István, PAKSY András, KÉKES Ede

[Authors had performed an anthropometric analysis using a database of 2011-2013 of Hungarian Hypertension Register. They analyzed overweight and obesity in relation of age. The results were compared with similar analysis conducted in the total population 2015. They analyzed the prevalence of visceral obesity as well using the waist circumference measurement categories and these were also compared with screening data of total population. The prevalence of overweight and obesity was very high in both genders, co-occurrences exceeded 70% between 45-70 years. The prevalence was significantly higher in hypertensives, than in the total population. The prevalence of visceral obesity measured by waist circumference was also high, especially in women whose reached 50% of cases. They observed a significant difference between hypertensive and total populations In category „danger” of visceral obesity]

Clinical Neuroscience

[The effect of angiotensin receptor blockers in cerebrovascular disorders and dementia: Bonus in addition to the antihypertensive effect]

KOVÁCS Tibor

[Hypertension and dementia are frequent disorders or rather syndromes. Their incidence is growing with advancing age and hypertension is increasing the risk of cognitive impairment too, while treating hypertension (i.e. the use of antihypertensive medications) is decreasing it. In addition, hypertension is the most important risk factor for stroke. The renin-angiotensin system (RAS) has a special role in the development of hypertension and also involved in the pathogenesis of the most frequent dementia form, namely Alzheimer’s disease. The effect of angiotensin convertase inhibitors and angiotensin receptor blockers (ARB) is based on the inhibition of the RAS, but the ARBs do not inhibit angiotensin formation, just blocking its harmful effects on the AT1 receptor, while allowing the activation of AT2 receptors with pleiotropic effects. Preclinical, epidemiological and clinical therapeutic studies suggest this additional effect of ARBs and these are summarized in this review.]